Suppr超能文献

美国食品药品监督管理局近期批准的IntelliSep检测(脓毒症生物标志物)用于脓毒症早期诊断的临床效用:与其他生物标志物的比较

Clinical Utility of Recently Food and Drug Administration-Approved IntelliSep Test (Sepsis Biomarker) for Early Diagnosis of Sepsis: Comparison with Other Biomarkers.

作者信息

Sarani Nima, Dasgupta Amitava, Enders Maria, Rowan Lauren, Elsarraj Hanan, Gralnek Sarah, Shay Madison, Lemar Lucas R, Simpson Steven Q, Cunningham Mark T, Zheng X Long

机构信息

Department of Emergency Medicine, The University of Kansas Medical Center, Kansas City, KS 66160, USA.

Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66160, USA.

出版信息

J Clin Med. 2024 Aug 16;13(16):4852. doi: 10.3390/jcm13164852.

Abstract

IntelliSep by Cytovale has received United States (U.S.) Food and Drug Administration (FDA) approval as a sepsis biomarker test. However, the clinical utility of this new test is not assessed in emergency departments. We investigated the clinical utility of this test using 44 patients visiting the emergency department at The University of Kansas Medical Center by comparing it with the monocyte distribution width (MDW) and other biomarkers including the von Willebrand factor (vWF) and ADAMTS13. IntelliSep assesses the cellular host response via deformability cytometry of biophysical leukocyte properties and produces a score (IntelliSep Index; ISI: from 0.1 (lowest risk) to 10 (highest risk). We measured the ISI in 44 patients (19 high probability and 25 low probability of sepsis groups) using EDTA-anticoagulated blood. Left over plasma was used for measuring the plasma von Willebrand factor (vWF) and ADAMTS13 antigen by ELISA assays. The MDW was obtained during routine CBC analysis using a Beckman hematology analyzer. The lactate and high-sensitivity troponin I levels were measured using a Beckman analyzer. Procalcitonin was measured using a Cobas e801 analyzer. The median ISI was twofold higher in the high-probability group than in the low-probability group ( < 0.01) while the median MDW was 34.5% higher in the high-probability group than in the low-probability group ( < 0.01). However, the correlation between the ISI and MDW was only modest (r = 0.66). In addition, significantly higher levels of plasma vWF antigen but lower levels of plasma ADAMTS13 antigen in the high-probability group were found, resulting in significantly higher vWF/ADAMTS13 ratios in the high-probability group than in the low-probability group. The new IntelliSep test along with vWF/ADAMTS13 ratios may be useful for the early diagnosis of sepsis in patients visiting the emergency department, which appears to be superior to the traditional marker, MDW.

摘要

Cytovale公司的IntelliSep已获得美国食品药品监督管理局(FDA)批准,作为一种脓毒症生物标志物检测方法。然而,该新检测方法在急诊科的临床实用性尚未得到评估。我们通过将堪萨斯大学医学中心急诊科的44名患者与单核细胞分布宽度(MDW)以及包括血管性血友病因子(vWF)和含血小板解聚蛋白及金属蛋白酶13(ADAMTS13)在内的其他生物标志物进行比较,研究了该检测方法的临床实用性。IntelliSep通过对生物物理白细胞特性进行变形性细胞计数来评估细胞宿主反应,并产生一个分数(IntelliSep指数;ISI:从0.1(最低风险)到10(最高风险))。我们使用乙二胺四乙酸(EDTA)抗凝血液对44名患者(19名脓毒症高概率组和25名低概率组)测量了ISI。剩余血浆用于通过酶联免疫吸附测定(ELISA)法测量血浆血管性血友病因子(vWF)和ADAMTS13抗原。MDW是在使用贝克曼血液分析仪进行常规全血细胞计数(CBC)分析时获得的。乳酸和高敏肌钙蛋白I水平使用贝克曼分析仪进行测量。降钙素原使用Cobas e801分析仪进行测量。高概率组的ISI中位数比低概率组高两倍(<0.01),而高概率组的MDW中位数比低概率组高34.5%(<0.01)。然而,ISI与MDW之间的相关性仅为中等(r = 0.66)。此外,发现高概率组的血浆vWF抗原水平显著更高,但血浆ADAMTS13抗原水平更低,导致高概率组的vWF/ADAMTS13比值显著高于低概率组。新的IntelliSep检测方法以及vWF/ADAMTS13比值可能有助于急诊科患者脓毒症的早期诊断,这似乎优于传统标志物MDW。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f42f/11355800/bc630a36060f/jcm-13-04852-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验